Evidence map›Paper›PMID 28455644›Full record

ReviewCurrent osteoporosis reports2017

Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.

Mark R Hanudel, Isidro B Salusky

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current osteoporosis reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Management of rickets: the new horizons for the pediatrician.Journal of health, population, and nutrition · 2025
    Review
  4. Malnutrition management in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Pediatric CKD-MBD: existing and emerging treatment approaches.Pediatric nephrology (Berlin, Germany) · 2022
    Article
  11. Article
  12. Bone Disease in CKD in Children.Calcified tissue international · 2021
    Review
  13. Review
  14. Bone Health in Childhood Chronic Disease.Endocrinology and metabolism clinics of North America · 2020
    Review
  15. Bone Health in Glomerular Kidney Disease.Current osteoporosis reports · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mark R HanudelDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mhanudel@mednet.ucla.edu.
Isidro B SaluskyDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

UCLA Child Health Research Career Development AwardK12HD034610 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEVASKAR, SHERIN U · 2002 to 2017
$6.6M
Regulation of Bone Mineralization in Renal OsteodystrophyR01DK035423 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 1986 to 2012
$4.9M
Regulation of Fibroblast Growth Factor 23 by Iron and Anemia in Chronic Kidney DiseaseK08DK111980 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HANUDEL, MARK ROBERT · 2016 to 2019
$758k
Phosphate Binders in Children with Chronic Kidney Disease-Mineral Bone DisorderU34DK104619 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 2015 to 2015
$395k
NICHD NIH HHS K12 HD034610NIDDK NIH HHS K08 DK111980NIDDK NIH HHS L40 DK106813NIDDK NIH HHS R01 DK035423NIDDK NIH HHS U34 DK104619
6 · The paper itself

Abstract

purpose of reviewIn this paper, we review the pathogenesis and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), especially as it relates to pediatric CKD patients. RECENT

findingsDisordered regulation of bone and mineral metabolism in CKD may result in fractures, skeletal deformities, and poor growth, which is especially relevant for pediatric CKD patients. Moreover, CKD-MBD may result in extra-skeletal calcification and cardiovascular morbidity. Early increases in fibroblast growth factor 23 (FGF23) levels play a key, primary role in CKD-MBD pathogenesis. Therapeutic approaches in pediatric CKD-MBD aim to minimize complications to the growing skeleton and prevent extra-skeletal calcifications, mainly by addressing hyperphosphatemia and secondary hyperparathyroidism. Ongoing clinical trials are focused on assessing the benefit of FGF23 reduction in CKD. CKD-MBD is a systemic disorder that has significant clinical implications. Treatment of CKD-MBD in children requires special consideration in order to maximize growth, optimize skeletal health, and prevent cardiovascular disease.

Indexed as

CalcinosisCardiovascular DiseasesChildChronic Kidney Disease-Mineral and Bone DisorderFibroblast Growth Factor-23Fractures, BoneHumansHyperparathyroidism, SecondaryHyperphosphatemiaPhosphorus, DietaryFGF23 protein, humanFibroblast Growth Factor-23Phosphorus, DietaryChildrenChronic kidney diseaseCKD-mineral and bone disorderPathogenesisTreatment of CKD-MBD

Identifiers

PMID28455644
PMCPMC5607746
OpenAlexW2607567581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.